• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Association of DHEAS levels with COVID19 severity, gender, age, comorbidities, and management strategies

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Jul 1;15(1):21348.
doi: 10.1038/s41598-025-05919-9. Association of DHEAS levels with COVID19 severity, gender, age, comorbidities, and management strategies

Tahereh Jamali[SUP] 1 [/SUP], Sussan Kaboudanian Ardestani[SUP] 2 [/SUP], Mohammad-Reza Vaez-Mahdavi[SUP] 3 4 [/SUP], Arezou Rezaei[SUP] 5 [/SUP], Mohammad Mehdi Naghizadeh[SUP] 6 [/SUP], Fatemeh Tuserkani[SUP] 1 [/SUP], HosseinAli Khazaei[SUP] 7 [/SUP], Ali Khodadadi[SUP] 8 9 [/SUP], Bahman Khazaei[SUP] 7 [/SUP], Keivan Latifi[SUP] 10 [/SUP], Tooba Ghazanfari[SUP] 11 12 [/SUP]



Affiliations
Abstract

COVID-19 has globally impacted millions. This study investigates DHEAS (dehydroepiandrosterone sulfate) as a factor for COVID-19 progression, analyzing its relationship with disease status, temporal patterns, age, gender, and comorbidities to improve outcomes. DHEAS was quantified with a competitive chemiluminescent immunoassay. We conducted DHEAS analysis across different days. COVID-19 patients, particularly inpatients, have lower DHEAS levels compared to controls. DHEAS levels in COVID-19 patients showed a dynamic pattern, with an initial decline followed by recovery. The scatter plot analysis suggested COVID-19 could increase the age-related decline in DHEAS among males. Comorbidities, including hypertension, heart disease, and diabetes mellitus, were prevalent among COVID-19 patients and correlated with disease severity. Hypertension moderated the relationship between hospitalization and DHEAS, especially in females. Our findings showed a significant association between lower DHEAS and COVID-19 severity, along with temporal dynamics. COVID-19's potential to increase the age-related decline in DHEAS, especially in males, underscores its intricate relationship with age. Hypertension's influence on DHEAS suggests a gender-specific effect, emphasizing tailored management approaches. These findings offer valuable insights into the interaction between COVID-19, hormonal dynamics, and demographic factors, suggesting that DHEAS levels may play a role in the pathophysiology of the disease and could be considered alongside other markers.

Keywords: COVID-19; Comorbidity diseases; DHEAS; Inpatients; Outpatients.

 
Back
Top Bottom